The Journal of Practical Medicine ›› 2022, Vol. 38 ›› Issue (23): 2903-2907.doi: 10.3969/j.issn.1006⁃5725.2022.23.003

• Clinical Advances • Previous Articles     Next Articles

A progress on immunotherapy for childhood acute lymphoblastic leukemia

PENG Sijing*,LU Jielun WANG Zicheng,ZENG Xiaozhen,ZOU Yawei.   

  1. Department of Pediatrics,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China

  • Online:2022-12-10 Published:2022-12-10
  • Contact: ZOU Yawei E⁃mail:zywyhscg@qq.com

Abstract:

Acute lymphoblastic leukemia(ALL)is the most common hematologic malignancy in children. The prognosis of ALL in pediatric patients has significantly improved in recent years. However,for pediatric popu⁃ lation with relapsed/refractory ALL,conventional chemotherapy has a low remission rate and provides no promising prognosis. With the emergence of immunotherapy,immunotherapies targeting ALL antigen ⁃associated monoclonal antibodies and chimeric antigen receptor T cells have shown to be effective against ALL,significantly improving the prognosis in patients with relapsed/refractory ALL. In this article,we review the immunotherapy for ALL in children.

Key words:

acute lymphoblastic leukemia, immunotherapy, children, antibody, chimeric antigen receptor